Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review

Table 4 Genotype and liver fibrosis stage for the 8 included studies

Ref.	Genotype (n)				Method	Liver fibrosis stage
	1	2	3	4		0	1	2	3	4	5	6
Apolinario et al[9]	43	20			Scheuer score	28		35
Lagging et al[34]4	1701	231	491	111	Ishak score	11	61	65	30	15	20	14
IL28B rs12979860 CC	44	13	33	3		3	18	27	11	5	12	5
IL28B rs12979860 CT	96	7	15	5		7	35	27	17	7	6	6
IL28B rs12979860 TT	30	3	1	3		1	8	11	2	3	2	3
Diago et al[7]	103	9	25		Ishak score	106				31
Fattovich et al[21]	92	87	47		Metavir2	121			21
Kurelac et al[33]	46				Ishak		34			12
Darling et al[31]	272				Ishak	220				52
Darbala et al[32]				159	Scheuer score		109		50
Ashgar et al[19]				64	Metavir	343			10 3

¹Baseline information for the sub analysis of IL28 12979860. Two hundred and fifty-two patients are reported to be enrolled, however adding the genotypes yields 253 patients. Likevise biopsies from 228 patients are described, however when adding the Ishak scores only yields 216 patients;

²Biopsies only available for 142 patients;

³Histology available for 44 patients;

⁴Lagging et al provided baseline demographics in accordance with IL-28 genotype (only baseline characteristics for rs12979860 are reported in the review, as these were representative for the study population). A box stretching over two - or more genotypes or fibrosis stage, indicates that the number refers to the combined group.